REVBREVELATION BIOSCIENCES, INC.

Nasdaq revbiosciences.com


$ 1.11 $ -0.05 (-4.31 %)    

Wednesday, 28-Aug-2024 15:59:48 EDT
QQQ $ 468.16 $ -5.41 (-1.13 %)
DIA $ 411.36 $ -1.55 (-0.38 %)
SPY $ 558.32 $ -3.26 (-0.58 %)
TLT $ 97.88 $ -0.12 (-0.12 %)
GLD $ 231.76 $ -1.64 (-0.7 %)
$ 1.11
$ 1.13
$ 1.11 x 460
-- x --
$ 1.10 - $ 1.15
$ 0.81 - $ 28.20
297,397
na
1.82M
$ 1.40
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-09-2024 06-30-2024 10-Q
2 05-10-2024 03-31-2024 10-Q
3 03-22-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-11-2023 06-30-2023 10-Q
6 05-22-2023 03-31-2023 10-Q
7 03-30-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-15-2022 06-30-2022 10-Q
10 05-14-2022 03-31-2022 10-Q
11 04-15-2022 12-31-2021 10-K
12 10-29-2021 09-30-2021 10-Q
13 08-23-2021 06-30-2021 10-Q
14 06-22-2021 03-31-2021 10-Q
15 03-31-2021 12-31-2020 10-K
16 11-16-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 revelation-biosciences-q2-2024-gaap-eps-513

Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(5.13) per share.

 watching-revelation-biosciences-zacks-small-cap-research-gives-stock-1240-price-valuation

https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_07082024_REVB_Sorensen.pdf

 why-is-nano-cap-revelation-biosciences-stock-skyrocketing-on-monday

Revelation Biosciences reveals positive safety and biomarker data from its Phase 1 study (RVL-HV02) of Gemini. The study met it...

 revelation-biosciences-announces-phase-1-results-for-gemini-demonstrates-safety-tolerability-and-dose-dependent-biomarker-changes-enables-further-development-across-multiple-indications

-Gemini administration induced statistically significant, dose dependent changes in key biomarkers of activity--Gemini was safe...

 revelation-biosciences-q1-eps-246-misses-177-estimate

Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(2.46) per share which missed the analyst consensus estimate...

 revelation-biosciences-q4-eps-833-beats-1377-estimate

Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(8.33) per share which beat the analyst consensus estimate o...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION